Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) saw a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 7,726 shares, a decrease of 74.1% from the December 31st total of 29,780 shares. Based on an average trading volume of 32,128 shares, the short-interest ratio is presently 0.2 days. Currently, 1.1% of the company’s stock are sold short. Currently, 1.1% of the company’s stock are sold short. Based on an average trading volume of 32,128 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

QNRX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, December 22nd. Wall Street Zen upgraded Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, November 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Quoin Pharmaceuticals Trading Down 4.1%

Shares of NASDAQ:QNRX traded down $0.39 on Wednesday, hitting $9.06. 31,739 shares of the company were exchanged, compared to its average volume of 32,541. The firm has a market capitalization of $7.61 million, a P/E ratio of -0.28 and a beta of 1.59. Quoin Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $41.80. The stock’s 50 day moving average price is $14.06 and its 200 day moving average price is $10.98.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its earnings results on Thursday, November 6th. The company reported ($6.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.36) by ($0.35). On average, equities analysts predict that Quoin Pharmaceuticals will post -2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Aberdeen Group plc purchased a new position in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $1,082,000. Aberdeen Group plc owned 8.93% of Quoin Pharmaceuticals at the end of the most recent quarter. 8.63% of the stock is owned by hedge funds and other institutional investors.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.